Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness of ADL5859 in relieving the pain
associated with diabetic peripheral neuropathy (DPN) compared with placebo and duloxetine (a
marketed drug approved for the treatment of painful DPN). The pain symptoms of DPN are
thought to be due to damage to nerves caused by the diabetes.